Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis

This publication has 18 references indexed in Scilit:

• The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
  Blood, 2006
• Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma
  British Journal of Haematology, 2006
• Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience
  Bone Marrow Transplantation, 2005
• Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
  American Journal of Hematology, 2005
• Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
  Bone Marrow Transplantation, 2004
• Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
  Blood, 2004
• Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
  New England Journal of Medicine, 2003
• High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial
  Bone Marrow Transplantation, 2003
• Spontaneous rupture of the spleen in AL amyloidosis
  American Journal of Hematology, 2003
• Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
  Amyloid, 2003